ABSTRACT BOOK INVITED SPEAKERS' ABSTRACTS



A new ERA for global Dermatology 10 - 15 JUNE 2019 MILAN, ITALY

AUTOIMMUNE BULLOUS DISEASES

AUTOANTIBODY PROFILE OF COHORT OF ITALIAN PATIENTS WITH LINEAR IGA DERMATOSIS

G Gasparini ⁽¹⁾ - E Cozzani ⁽¹⁾ - G Di Zenzo ⁽²⁾ - A Salemme ⁽²⁾ - A Agnoletti ⁽¹⁾ - C Vassallo ⁽³⁾ - M Caproni ⁽⁴⁾ - E Antiga ⁽⁴⁾ - A Marzano ⁽⁵⁾ - R Cavalli ⁽⁶⁾ - C Ocella ⁽⁷⁾ - C De Simone ⁽⁸⁾ -Aurora Parodi ⁽¹⁾

University of Genoa, Dermatology Department, Department of Health Sciences, Genoa, Italy ⁽¹⁾ - IDI-IRCCS, Laboratory of Molecular and Cell Biology, IDI-IRCCS, Rome, Italy ⁽²⁾ -Fondazione IRCCS Policlinico San Matteo, Institute of Dermatology, Department of Clinical-Surgical, Diagnostic, and Pediatric Science, Pavia, Italy ⁽³⁾ - University of Florence, Section of Dermatology, Department of Surgery and Translational Medicine, Florence, Italy ⁽⁴⁾ -Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UOC Dermatologia, Milan, Italy ⁽⁵⁾ - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, UOC Dermatologia Pediatrica, Milan, Italy ⁽⁶⁾ - IRCCS G. Gaslini Children's Hospital, Dermatology Unit, Department of Surgery and Intensive Care,, Genoa, Italy ⁽⁷⁾ - Catholic University of the Sacred Heart, Dermatology Department, Rome, Italy ⁽⁸⁾

Introduction: Linear IgA bullous disease (LABD) is an IgA-mediated autoimmune bullous disorder of adults and children, characterized by sub-epidermal blisters and linear deposits of IgA at the basement membrane zone (BMZ). LABD is immunologically heterogeneous with autoantibodies direct against various hemidesmosomal antigens.

Objective: To characterize the humoral response in a cohort of Italian patients with LABD. Secondly, to demonstrate LAD-1 as major autoantigen in patients affected by the lamina lucida LABD subtype.

Material and Methods: A retrospective multicentric study was conducted on 60 patients with LABD. Reactivity profile of patients' sera was investigated by indirect immunofluorescence (IIF) on monkey oesophagus, IIF on salt-split skin (SSS), ELISA testing for anti-BP180 and anti-BP230 IgG and IgA, and immunoblotting for the detection of IgA autoantibodies based on affinity purified LAD-1.

Results: IIF showed anti-BMZ IgA in 13% of patients' sera. IgA deposition at IIF-SSS showed a lamina lucida pattern, a sub-lamina densa pattern and a mixed pattern in 45%, 3% and 13% of patients sera respectively. On ELISA testing 30% of patients had anti-BP180-NC16A IgA and 25% had anti-BP230 IgA. IgA reactivity to LAD-1 on IB was found in 48% of patients' sera. Out of the 27 patients with a lamina lucida binding pattern, 70%











had reactive IgA to LAD-1 on IB. Overall IgG autoantibodies detected by either IIF-SSS or ELISA testing were found in 22% of cases.

Conclusions: LABD is characterized by an heterogenous humoral response, comprising mainly IgA and to a lesser extent IgG autoantiboides. Whether all of these auto-antibodies have an actual pathogenicity is still to be established. Several BMZ antigens are targeted by autoantibodies in LABD. LAD-1 is a major auto-antigen of the lamina lucida subtype. Direct immunofluorescence remains the golden standard for LABD diagnosis, as IIF, IB, and ELISA testing for circulating IgAs show lower sensitivity.





International League of Dermatological Societies *Skin Health for the World*

